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A remarkable attempt was made to prepare timolol maleate ocuserts, which is 
significant beta adreno receptor antagonist, by the aid of different of different ratio of 
composition of polymers such as EC, HPMC and Eudragit RS 100. Twelve batches of suitable 
ophthalmic films formulated by the method of solvent casting technique. Out of which the 
best formulation was found out the zero order release was observed in batch and was 
considered as the least drug releasing one. The formulated ocuserts were flexible, uniform 
and was meant for physic-chemical evaluator parameters, in vitro drug release profile and in 
vivo evaluation made on male rabbit. 
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Timolol maleate ocuserts were 
prepared using different polymers such as 
EC, HPMC and Eudragit RS 100 at various 
concentrations.  The in vitro release of the 
drug from the formulations was studied 
using commercial semi permeable membrane. 
The physicochemical parameters of ocuserts 
were evaluated.  Zero order release for one 
day was observed in formulation I.   (Drug 
reservoir with 1.25% HPMC and 1.25% EC 
and 2% HPMC as rate controlling membrane)  
The field of ocular drug delivery is one of the 
most interesting and challenging endeavors 
facing by the pharmaceutical scientist for past 
10-20 years.  As an isolated organ eye is very 
difficult to study from a drug delivery point 
of view (Jain 1997).  Despite of these 
limitations, improvements have been made 
with objective of maintaining the drug in the 
bio phase for an extended period. 
Timolol maleate is a beta adreno 
receptor antagonist, which can be used in 
glaucoma, by reducing intraocular pressure.  
It is presently available as eye drops but has 
several drawbacks such as loss of drug from 
tear flow, lachrymal and nasal drainage and 
patient non-compliance.  In this study and 
attempt was made to prepare ocular inserts 
with the target of increasing the contact time, 
reducing the frequency of administration, 
improving patient compliance and obtaining 
greater therapeutic efficiency. 
 
Materials and Methods  
Timolol maleate was obtained from 
Centaur pharmaceuticals Pvt. Ltd.  The 
polymers used were hydroxy propyl 
methylcellulose (HPMC 15 cps), ethyl 
Eudragit RS 100 were procured from Micro 
Labs, Hosur. 
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Preparation of drug reservoir 
The reservoir films containing 8.75mg 
of timolol maleate with different polymers at 
various concentrations were casted on 
mercury surface using a ring of 4cm diameter 
having 5mL capacity, after drying at room 
temperature for 24 h, circular films of 8mm 
diameter (an area of 0.5024 cm2), each 
containing 0.35mg drug are cut. 
 
Preparation of rate controlling membrane 
The rate controlling membrane was 
casted on mercury surface using hydroxyl 
propyl methylcellulose as polymer and 
Dibutyl phthalate (30% W/W of polymer) as 
plasticizer and circular membranes of 10 mm 
diameter were cut using special mould.  Both 
sides of the drug reservoir were sealed to 
control the release from periphery. 
 
In vitro release studies 
The in vitro release studies were 
carried out using bi chambered donor-
receiver compartment model (Manvi 1997) 
designed using commercial semi permeable 
membrane of transparent and regenerated 
cellulose type (Sigma dialysis membrane). It 
was tied at one end of the open-end cylinder, 
which acted as the donor compartment.  The 
ocuserts was placed inside the donor 
compartment.  The semi permeable 
membrane was used to stimulate ocular in 
vivo conditions like corneal epithelial barrier.  
In order to stimulate the tear volume, 0.7mL 
of phosphate buffer was placed and 
maintained at the same level throughout the 
study in the donor compartment, which 
contain 25 mbf distilled water and stirred 
continuously using a magnetic stirrer.  
Samples of 1 mL were withdrawn from the 
receptor compartment at periodic intervals 
and replaced with equal volume of phosphate 
buffer.  The drug content was analyzed at 294 
nm3 against reference standard using 
phosphate as blank on a shimadzu UV visible 
spectrophotometer. 
Evaluation of ocuserts 
The prepared ocuserts were evaluated 
for moisture absorption, moisture loss, 
thickness, weight variation and drug content.  
Formulation I (drug reservoir with 1.25% 
HPMC and 1.25% EC and 2% HPMC as rate 
controlling membrane) was sterilized by 
using ethylene oxide (Koteshwar 1992).  The 
test for sterility of formulation I was carried 
out according to the method prescribed in 
Indian Pharmacopoeia.  Physical stability and 
drug integrity of formulation I were studied 
using Fourier Transform infrared 
spectrophotometer-410 in pre- and post-
sterilization conditions. 
 
In vivo studies 
Male rabbits (Orytolagus cuniculus), 
10-12 weeks old weighing 2.5 to 3 kg were 
selected.  They kept three per cage with husk 
bedding and were fed with standard rodent 
pellet diet and water.  Light and dark cycle of 
12 h was maintained throughout the study.  
The temperature, relative humidity 
conditions were 28±2 and 60±15% 
respectively. 
A set of healthy rabbits (6 males) were 
selected and were checked for absence of any 
diseases including ophthalmic type.  
Sterilized ocuserts of formulation I (drug 
reservoir with 1.25% HPMC and 1.25% EC 
and 2% HPMC as rate controlling membrane) 
was used for present study content (Sane 
1992). 
 
Results and Discussion 
In the present study, efforts were 
made to prepare ocular inserts of Timolol 
Maleate using different polymers such as 
HPMC, EC, Eudragit RS 100 and Eudragit RL 
100 Table 1.  The drug delivery system was 
designed as a matrix and the release was 
controlled by using polymeric rate controlling 
membrane. 
The physicochemical evaluation 
(Elhance 1984) of data of (Table 2, 3) indicates 
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that percentage of moisture absorption is 
more in formulation IV (drug reservoir with 
2.5% HPMC and 2.5% C and 2% HPMC as 
rate controlling membrane).  This may be due 
to the hydrophobic ethyl cellulose membrane 
and comparatively low concentration of 
polymers. Though percentage of moisture 
absorption and the percentage of moisture 
loss are high, there is no change in the 
integrity at high humid and dry conditions. 
 
Table 1 Stability studies on the formulation I 
Day Drug Content (mg) 
4o 37o 60o 
0 0.354 0.354 0.354 
5 0.352 0.352 0.350 
12 0.349 0.347 0.345 
21 0.345 0.342 0.338 
Each value represents an average of two readings.  
*The formulation become rigid and brittle which 
was originally smooth and flexible. 
 
Table 2 Composition of various polymers and plasticizers in different formulations 
 
 
Formula-
tion code 
 
Drug reservoir 
Rate 
controlling 
membrane 
 
Plasticizer 
EC HPMC HPMC Dibutyl 
phthalate 
F-I 1.25 2 2 30 % W/W 
F-II 2.5 1.25 2 30 % W/W 
F-III 1.25 2.5 2 30 % W/W 
F-IV 2.5 2.5 2 30 % W/W 
 EUDRL 100 HPMC   
F-V 1.25 1.25 2 30 % W/W 
F-VI 1.25 2.5 2 30 % W/W 
F-VII 2.5 1.25 2 30 % W/W 
F-VIII 2.5 2.5 2 30 % W/W 
 EUDRL100 EUDRS100   
F-IX 1.25 1.25 2 30 % W/W 
F-X 2.5 1.25 2 30 % W/W 
F-XI 1.25 2.5 2 30 % W/W 
F-XII 2.5 2.5 2 30 % W/W 
                                                    
Table 3 Physicochemical evaluation of ocuserts of Timolol Maleate 
Formula-
tion code 
PMA ±  SD PML ±  SD Thickness in 
mm ± SD 
Weight 
uniformity 
in mg  ± SD 
Folding 
Endurance 
± SD 
Drug 
content in 
mg ±  SD 
F-I 5.02 ± 0.38 22.24 ±0.24 0.232 ± 0.007 20.48 ±0.74 76 ± 1.74 0.354 ± 0.148 
F-II 5.28 ± 0.26 24.82 ±0.42 0.247 ± 0.007 21.74 ±0.65 77 ± 1.16 0.358 ± 0.094 
F-III 5.89 ± 0.09 22.94 ±0.04 0.258 ± 0.008 22.08 ±0.24 79 ± 2.08 0.346 ± 0.125 
F-IV 6.58 ± 0.19 20.71 ±0.33 0.296 ± 0.011 24.80 ±0.77 82 ± 1.84 0.362 ± 0.115 
F-V 5.08 ± 0.36 22.54 ±0.28 0.302 ± 0.000 22.28 ±0.65 80 ± 1.24 0.346 ± 0.280 
F-VI 5.22 ± 0.24 21.43± 0.11 0.312 ± 0.012 23.84± 0.82 82 ± 1.16 0.312 ± 0.012 
F-VII 5.16 ± 0.42 18.21 ±0.01 0.318 ± 0.000 24.26 ±0.28 83 ± 2.08 0.361 ± 0.156 
F-VIII 5.78 ± 0.36 15.38 ±0.12 0.324 ± 0.008 25.20 ±0.16 85 ± 1.34 0.352 ± 0.550 
F-IX 4.86 ± 0.11 16.18 ±0.31 0.316 ± 0.009 23.80 ±0.46 84 ± 1.15 0.360 ± 0.112 
F-X 4.38 ± 0.89 15.76 ±0.85 0.328 ± 0.013 24.46 ±0.25 86 ± 2.16 0.362 ± 0.216 
F-XI 3.76 ± 0.38 13.48 ±0.52 0.334 ± 0.092 24.89 ±0.84 85 ± 1.94 0.355 ± 0.128 
F-XII 3.62 ± 0.06 11.14 ±0.89 0.344 ± 0.008 25.80 ±0.76 88 ± 2.18 0.348 ± 0.174 
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Thickness of the ocuserts varies 
between (0.232 to 0.344).  The formulations 
are not very thicker and coinciding with 
ocuserts of Pile20 marketed in US by Alza 
corporation and do not produce any irritation 
while placing and being in cul-de-sac. The 
minimum standard deviation values reveled 
the fact that process used in the study is 
capable of giving films of uniform 
magnitude. 
 
In vitro dissolution study of 
formulation I (drug reservoir with 1.25% 
HPMC and 1.25% EC and 2% HPMC as rate 
controlling membrane) was found to release 
in a zero order pattern for the extended 
period of 24 h.  It also fulfilled many 
requirements of novel “Once a day” delivery 
system.  Hence, it was considered as the 
formulation of choice for in vivo studies. 
 
In vivo release studies have shown 
that the formulation I (drug reservoir with 
1.25% HPMC and 1.25% EC and 2% HPMC as 
rate controlling membrane) is capable of 
releasing the drug for 24h almost in the same 
pattern, which was found in in vitro studies. 
The delivery system was found to release 
88.93% of loaded drug at the end of 24 h.  The 
regression analysis6 was carried to establish 
correlation between in vitro and in vivo release 
data.  The correlation value of ± 0.9876 
indicated correctness of the in vitro method 
followed and adaptability of the delivery 
system to the biological system where it can 
release the drug in concentration 
independent manner. Formulation I (drug 
reservoir with 1.25% HPMC and 1.25% EC 
and 2% HPMC as rate controlling membrane) 
passed the test for sterility. 
Accelerated stability study was 
carried out for formulation I (drug reservoir 
with 1.25% HPMC and 1.25% EC and 2% 
HPMC as rate controlling membrane) by 
exposing the ocular inserts at 4o C, 37oC and 
60o C.  Drug integrity at accelerated storage 
condition was checked by IR spectral 
analysis. 
 
Conclusion 
Formulation I (drug reservoir with 
1.25% HPMC and 1.25% EC and 2% HPMC as 
rate controlling membrane) has achieved the 
targets of present study such as increased 
residence time, prolonged zero order release, 
reduction in the frequency of administration 
and thus may improve patient compliance. 
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